Jasper Therapeutics (JSPR) Other Non-Current Liabilities (2019 - 2026)

Jasper Therapeutics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $2.5 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 12.37% year-over-year to $2.5 million in Q2 2026; TTM through Jun 2026 was $2.5 million, a 12.37% increase from a year earlier, with the FY2025 full-year figure at $16.2 million, up 602.78% from the prior year.
• Other Non-Current Liabilities was $2.5 million for Q2 2026 at Jasper Therapeutics, down from $16.2 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $22.6 million in Q3 2025, with the low at $641000.0 in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $4.0 million, with a median of $2.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities sank 92.82% in 2022, then jumped 897.92% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $2.4 million in 2022, then retreated by 3.78% to $2.3 million in 2023, then grew by 1.59% to $2.3 million in 2024, then jumped by 602.78% to $16.2 million in 2025, then plunged by 84.26% to $2.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.5 million (Q2 2026), $16.2 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.